



Washington State Health Care Authority
Prescription Drug Program

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

November 19, 2020

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective January 1, 2021:

Antiemetic (5HT3) reviewed 8/15/2018		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
fosaprepitant dimeglumine	fosaprepitant dimeglumine solution	No	Yes
granisetron	granisetron HCL solution	No	Yes
	granisetron HCL tablet	No	Yes
ondansetron	ondansetron ODT tablet dispersible	No	Yes
ondansetron HCL	ondansetron HCL solution	No	Yes
	ondansetron HCL tablet	No	Yes

The effect of this recommendation is no change to the WA PDL.

Statin (HMG-CoA Reductase Inhibitor) reviewed 4/18/2018		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
atorvastatin calcium	atorvastatin calcium tablet	No	Yes
lovastatin	lovastatin tablet	No	Yes
pravastatin sodium	pravastatin sodium tablet	No	Yes
rosuvastatin calcium	rosuvastatin calcium tablet	No	Yes
simvastatin	simvastatin tablet	No	Yes

The effect of this recommendation is no change to the WA PDL.

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,

Donna Sullivan
Chief Pharmacy Officer
Clinical Quality and Care Transformation
Washington State Health Care Authority